Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Teriparatide Stories

2014-01-01 16:20:13

THOUSAND OAKS, Calif. and BRUSSELS, Jan. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels:UCB) today announced results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD). Published in the New England Journal of Medicine (NEJM), the trial demonstrated that, compared with placebo, romosozumab treatment for 12 months significantly increased BMD at the lumbar spine, total hip and femoral neck....

2013-05-29 08:30:49

INDIANAPOLIS, May 29, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data showing that FORTEO significantly increased lumbar spine volumetric bone mineral density (vBMD) compared to risedronate in men with glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis is caused by excess intake of glucocorticoids, a class of steroid hormones used to treat inflammatory, autoimmune and allergic disorders.(1) Study results are published in the June issue of...

2013-04-04 08:29:41

Greater Reduction in the Risk of Vertebral Fracture is One of the Greatest Unmet Needs in Osteoporosis and Osteopenia, According to a New Report from Decision Resources BURLINGTON, Mass., April 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European primary care physicians (PCPs) agree that efficacy on hip fracture risk reduction is one of the attributes that...

2012-12-12 08:27:50

BOONTON, N.J., Dec. 12, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society. The article will...

2012-10-15 11:28:29

INDIANAPOLIS, Oct. 15, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented data comparing the effects of FORTEO and zoledronic acid on transiliac crest bone biopsies at six months in postmenopausal women with osteoporosis, based on additional analysis of data from the SHOTZ trial. Results, which were presented in an oral presentation at the 2012 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Minneapolis, MN, clearly differentiate the...

2012-10-15 07:29:07

BOONTON, N.J., Oct. 15, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women was the subject of an oral presentation given by Morten Karsdal, MSc, PhD, Chief Executive Officer of Nordic Bioscience, at the ASBMR...

2012-09-20 14:24:00

THOUSAND OAKS, Calif., Sept. 20, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia(®) (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture. Prolia, the first FDA-approved RANK Ligand inhibitor, is a subcutaneous injection administered by a health care professional every six months. "While osteoporosis and osteoporosis-related fractures are more commonly...

2012-08-07 02:29:49

INDIANAPOLIS, Aug. 7, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced data from a Phase III trial comparing the effects of FORTEO(®) (teriparatide [rDNA origin] injection) and risedronate on back pain in postmenopausal women with osteoporotic vertebral fractures. The study showed no difference between FORTEO and risedronate on the primary endpoint of at least a 30 percent reduction in worst back pain from baseline to six months of therapy, as assessed by a numeric...

FDA Report Suggests Women Reassess Bone Drug Use Due To Serious Adverse Events
2012-05-11 12:45:33

A new analysis of popular bone-building drugs by the US Food and Drug Administration (FDA) could prompt millions of women to rethink their use of such drugs, even though the agency fell short of issuing specific recommendations. The FDA said doctors need to reassess which women are likely to benefit from bisphosphonates such as Fosamax, Actonel and Reclast, given the lack of concrete evidence that taking them over long periods really helps them and the possibility that they can put some...

Image 1 - Osteoporosis Patients Receive Medication From Implanted Microchips
2012-02-17 06:09:52

Seven Dutch women suffering from osteoporosis received bone-strengthening medication from implanted microchips as part of a first-of-its kind study of wirelessly controlled drug-releasing devices, according to research published Thursday in the journal Science Translational Medicine. According to Lauran Neergaard of the Associated Press (AP), the study, which was funded by Massachusetts-based implantable drug delivery device developer MicroCHIPS, Inc and headed up by MIT professors Robert...